NPI 1801561220: Open Payments
NPI 1801561220. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$227 in 12 payments from 8 companies in 2025. Trend: 2023 $311 · 2024 $16 · 2025 $227
Food & beverage: $227
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $53 |
| ABBVIE INC. | 3 | $52 |
| Amgen Inc. | 2 | $31 |
| Ardelyx, Inc. | 1 | $27 |
| Novo Nordisk Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
Products named: Kerendia, VRAYLAR, OTEZLA, IBSRELA, LINZESS, Ozempic, Veozah, NEXLETOL.
